LIVER INTERNATIONAL, with its ISSN 1478-3223 and E-ISSN 1478-3231, is a prestigious peer-reviewed journal published by Wiley in the United Kingdom. Established in 2003, it focuses on advancing the field of hepatology, covering a broad spectrum of topics including liver disease, hepatocellular carcinoma, and transplantation. Ranking #10 out of 82 in the Scopus category for Medicine - Hepatology and boasting a remarkable 88th percentile, LIVER INTERNATIONAL has secured its reputation as a leading journal, recognized as Q1 in the 2023 category quartiles. The journal emphasizes accessibility, offering an open access option to ensure that critical research findings reach a wider audience. By facilitating the dissemination of high-quality research, LIVER INTERNATIONAL plays a vital role in shaping contemporary hepatological discourse and bridging academic inquiry with clinical practice, making it an essential resource for researchers, healthcare professionals, and students alike.

JOURNAL OF HEPATOLOGY, published by Elsevier, stands as a preeminent source in the field of Hepatology, with its impact underscored by a remarkable 2023 Category Quartile of Q1 and a Scopus rank of 3rd out of 82 journals, placing it in the 96th percentile for the discipline. Since its inception in 1985, this journal has been a vital conduit for the dissemination of pioneering research, clinical studies, and reviews related to liver diseases and their impact on global health. Although it currently does not offer open access options, the journal is committed to providing top-tier content to its readership—researchers, medical professionals, and students—in order to advance knowledge and foster innovation in hepatology. With a broad and inclusive scope, it aims to cover significant breakthroughs, therapeutic advancements, and epidemiological studies, continually pushing the boundaries of understanding in liver health. The journal is based in Amsterdam, Netherlands, and remains an essential resource for those dedicated to the progression of hepatologic science.

Welcome to the Journal of Virus Eradication, a premier publication dedicated to advancing the field of virology and infectious disease research. Published by MEDISCRIPT LTD, this journal provides a vital platform for sharing cutting-edge research findings in key areas including epidemiology, immunology, and public health. With an impressive classification of Q2 in Epidemiology and Infectious Diseases for 2023, this journal exemplifies a commitment to high-quality scholarship and impactful research. The Journal of Virus Eradication is instrumental in disseminating knowledge that tackles viral threats, contributing to global health initiatives aimed at virus containment and eradication. Researchers, professionals, and students alike will find this journal an invaluable resource, making significant contributions to the scientific community and society at large.

Hepatology Research, ISSN 1386-6346 and E-ISSN 1872-034X, is a premier academic journal published by Wiley that serves the dynamic fields of Hepatology and Infectious Diseases. With an impressive 2023 impact factor and ranked Q2 in Hepatology and Q1 in Infectious Diseases, this journal stands out as a vital resource for researchers, professionals, and students. Covering a broad spectrum of topics related to liver health, the journal aims to disseminate cutting-edge research and insights from the converged years of 1997 to 2024. As an open-access platform, it fosters the global sharing of knowledge, providing valuable access to pioneering studies that address pressing issues in liver disease and its associated infections. Based in the United Kingdom, at 111 River St, Hoboken, NJ, Hepatology Research is pivotal for advancing scientific understanding and improving patient outcomes worldwide.

ANTIVIRAL THERAPY is a prominent academic journal dedicated to the field of infectious diseases and pharmacology, published by SAGE Publications Ltd in the United Kingdom. Since its inception in 1996, this journal has become an essential platform for disseminating cutting-edge research and innovative therapeutic approaches for viral infections, making significant contributions to advancements in medical science. With an HIndex indicating the quality and influence of its published work, ANTIVIRAL THERAPY holds prestigious rankings in its categories, including Q3 in Infectious Diseases and Pharmacology as of 2023. While it currently does not offer open access, the journal provides valuable insights that are crucial for researchers, healthcare professionals, and students engaged in antiviral research and treatment strategies. As it converges towards 2024, the journal continues to play a vital role in shaping the understanding and management of viral diseases, making it a critical resource for anyone involved in this important field of study.

Tuberculosis and Respiratory Diseases is a leading open-access journal published by THE KOREAN ACADEMY OF TUBERCULOSIS & RESPIRATORY DISEASES, dedicated to disseminating knowledge in the fields of infectious diseases and pulmonary medicine. Since its inception in 1980, the journal has undergone significant growth, currently recognized in the elite Q2 category for both Infectious Diseases and Pulmonary and Respiratory Medicine as of 2023. With an impact factor reflecting its esteemed position—ranked 52nd in its category—it serves as a vital resource for researchers and healthcare professionals seeking cutting-edge insights, studies, and advancements in the management and treatment of respiratory diseases, particularly tuberculosis. The journal is committed to providing open access to its content since 2013, ensuring that critical research is available to scholars worldwide, fostering collaboration and innovation in the global fight against respiratory illnesses.

INFECTION is a prestigious journal, published by Springer Heidelberg, that serves as a leading platform for the dissemination of critical research in the fields of Infectious Diseases, Microbiology, and Medicine. With an impressive Q1 ranking in multiple categories such as Infectious Diseases, Medicine (miscellaneous), and Medical Microbiology, the journal is recognized for its high-quality content and impactful contributions to the scientific community, as evidenced by its Scopus rankings placing it in the top 10th percentiles. Since its inception in 1973, and projected to continue until 2024, INFECTION has established itself as a vital resource for researchers, healthcare professionals, and students keen to explore the latest findings and advancements in infectious diseases. The journal provides a rigorous peer-review process, ensuring that only high-quality studies are published, making it an essential read for those seeking to deepen their understanding and stay abreast of the rapidly evolving landscape in infection research.

HEPATOLOGY is a premier scholarly journal dedicated to advancing the field of liver research and clinical practice. Published by Lippincott Williams & Wilkins, this journal boasts an impressive impact factor and holds a prestigious position as one of the top-ranked publications in both Hepatology (Q1) and Medicine (miscellaneous, Q1) categories as of 2023. HEPATOLOGY, with its commitment to disseminating high-quality research since its inception in 1981, serves as an essential platform for researchers, clinicians, and students focusing on liver diseases, including hepatitis, cirrhosis, and liver cancer. The journal's editorial board comprises leading experts who guide the publication towards its objective of fostering innovation and collaboration in this critical area of health. Although it does not offer an open access model, HEPATOLOGY ensures that its comprehensive analyses, reviews, and groundbreaking studies are accessible to the global medical community. Join the discourse in hepatology and be a part of a transformative journey through this indispensable resource.

Canadian Liver Journal, published by University of Toronto Press Inc., offers a dedicated platform for the dissemination of cutting-edge research in the field of Hepatology. With an E-ISSN of 2561-4444, this journal plays a pivotal role in advancing knowledge related to liver diseases and therapies, currently ranked in the 3rd quartile (Q3) for the 2023 category in Hepatology—a reflection of its growing influence in the biomedical research community. The journal, which has been in circulation since 2018 and sets its sights on contributing valuable insights until 2024, aims to engage researchers, clinicians, and students alike by providing a rigorous peer-reviewed environment for sharing findings, case studies, and reviews pertinent to liver health. Through its commitment to excellence and scholarly impact, the Canadian Liver Journal serves as an essential resource for those dedicated to combating liver diseases and enhancing patient care.

INTERVIROLOGY is a leading academic journal dedicated to advancing the field of virology and infectious diseases, published by KARGER. With a commendable history since its inception in 1973, the journal is currently poised to explore innovative virological research through to 2024. INTERVIROLOGY is indexed with the ISSN 0300-5526 and E-ISSN 1423-0100, reflecting its commitment to maintaining high scholarly standards. The journal is categorized within the Q3 quartile for both Infectious Diseases and Virology as of 2023, demonstrating its relevance and contribution to the academic community. With Scopus rankings placing it as #130 in Infectious Diseases and #41 in Virology, INTERVIROLOGY serves as an essential resource for researchers, professionals, and students seeking cutting-edge insights and discoveries in virology. While it currently operates under a subscription model, its rigorous peer-review process ensures a high quality of published content, making it a cornerstone for those dedicated to understanding and combating viral diseases.